Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 13 (May 1), 2006: pp. 2044-2051
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.03.3332

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eckardt, J. R.
Right arrow Articles by Ross, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eckardt, J. R.
Right arrow Articles by Ross, G.
Related Articles
Right arrowRelated Editorial

Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Zsolt Papai, Antoaneta Tomova, Valentina Tzekova, Theresa E. Crofts, Sarah Brannon, Paul Wissel, Graham Ross

From The Center for Cancer Care and Research, St Louis, MO; Zentralkrankenhaus Gauting, Gauting bei Muenchen, Germany; Koranyi National Institute of Pulmonology, Budapest, Hungary; Oncology Dispensary, Plovdiv, Bulgaria; University Hospital Tzaritza Joanna, Sofia, Bulgaria; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Harlow, United Kingdom

Address reprint requests to John Eckardt, MD, The Center for Cancer Care and Research, 12855 N Outer Forty Dr, Suite 200, St Louis, MO 63141; jeckardt{at}tcccr.com

PURPOSE: This open-label, randomized, multicenter phase III study compared oral topotecan/intravenous cisplatin (TC) with intravenous (IV) etoposide/cisplatin (PE) in patients with untreated extensive-disease small-cell lung cancer (ED-SCLC).

PATIENTS AND METHODS: A total of 784 patients were randomly assigned to either oral topotecan 1.7 mg/m2/d x 5 with IV cisplatin 60 mg/m2 on day 5 (n = 389) or IV etoposide 100 mg/m2/d x 3 with IV cisplatin 80 mg/m2 on day 1 (n = 395) every 21 days.

RESULTS: Overall survival (primary end point) was similar between groups (P = .48; median: TC, 39.3 weeks v PE, 40.3 weeks). One-year survival was 31% (95% CI, 27% to 36%) in both groups and the difference of –0.03 (95% CI, –6.53 to 6.47) met the predefined criteria of ≤ 10% absolute difference for noninferiority of TC relative to PE. Response rates were similar between groups (TC, 63% v PE, 69%). Time to progression was slightly but statistically longer with PE (log-rank P = .02; median: TC, 24.1 weeks v PE, 25.1 weeks). The regimens were similarly tolerable. Grade 3/4 neutropenia occurred more frequently with PE (84% v 59%), whereas grade 3/4 anemia and thrombocytopenia occurred more frequently with TC (38% v 21% and 38% v 23%, respectively). Lung Cancer Symptom Scale scores were statistically better with PE, but the differences were small and of debatable clinical significance.

CONCLUSION: Oral topotecan with cisplatin provides similar efficacy and tolerability to the standard (etoposide with cisplatin) in untreated ED-SCLC and may provide greater patient convenience compared with intravenous etoposide and cisplatin.

Supported by GlaxoSmithKline, Middlesex, United Kingdom.

Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004, and at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Editorial

  • Reponses to Topoisomerase-I Inhibitors in Extensive Small-Cell Lung Cancer: Chance or Chromosomes?
    Michael C. Perry
    JCO 2006 24: 1980-1981 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
B. Freidlin, E. L. Korn, S. L. George, and R. Gray
Randomized Clinical Trial Design for Assessing Noninferiority When Superiority Is Expected
J. Clin. Oncol., November 1, 2007; 25(31): 5019 - 5023.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. H. Lee, S.-W. Kim, K.-S. Bae, J.-S. Hong, C. Suh, Y.-K. Kang, and J.-S. Lee
A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer
Clin. Cancer Res., October 15, 2007; 13(20): 6182 - 6186.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. O'Brien, J. Eckardt, and R. Ramlau
Recent Advances with Topotecan in the Treatment of Lung Cancer
Oncologist, October 1, 2007; 12(10): 1194 - 1204.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. R. Simon and A. Turrisi
Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 324S - 339S.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
B. E. Lally, J. J. Urbanic, A. W. Blackstock, A. A. Miller, and M. C. Perry
Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?
Oncologist, September 1, 2007; 12(9): 1096 - 1104.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Gridelli, C. Langer, P. Maione, A. Rossi, and S. E. Schild
Lung Cancer in the Elderly
J. Clin. Oncol., May 10, 2007; 25(14): 1898 - 1907.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. C. Perry
Reponses to Topoisomerase-I Inhibitors in Extensive Small-Cell Lung Cancer: Chance or Chromosomes?
J. Clin. Oncol., May 1, 2006; 24(13): 1980 - 1981.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online